bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1 from Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Authors: Pereira Carolina , Gimenez-Xavier Pol , Pros Eva , Pajares Maria J. , Moro Massimo , Gomez Antonio , Navarro Alejandro , Condom Enric , Moran Sebastian , Gomez-Lopez Gonzalo , Graña Osvaldo , Rubio-Camarillo Miriam , Martinez-Martí Alex , Yokota Jun , Carretero Julian , Galbis Jose M. , Nadal Ernest , Pisano David , Sozzi Gabriella , Felip Enriqueta , Montuenga Luis M. , Roz Luca , Villanueva Alberto , Sanchez-Cespedes Montse
Published: April 2023

Supplementary Table 1A, B, C, D and E
Table S2 from Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Erbe Amy K. , Wang Wei , Carmichael Lakeesha , Kim KyungMann , Mendonça Eneida A. , Song Yiqiang , Hess Dustin , Reville Patrick K. , London Wendy B. , Naranjo Arlene , Hank Jacquelyn A. , Diccianni Mitchell B. , Reisfeld Ralph A. , Gillies Stephen D. , Matthay Katherine K. , Cohn Susan L. , Hogarty Michael D. , Maris John M. , Park Julie R. , Ozkaynak M. Fevzi , Gilman Andrew L. , Yu Alice L. , Sondel Paul M.
Published: April 2023

Incidence of KIR/KIR-ligand genotypes in the patients analyzed.
Sup. Fig. 4 from Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia
Authors: Budhraja Amit , Turnis Meghan E. , Churchman Michelle L. , Kothari Anisha , Yang Xue , Xu Haiyan , Kaminska Ewa , Panetta John C. , Finkelstein David , Mullighan Charles G. , Opferman Joseph T.
Published: April 2023

DHA represses MCL-1 in TKI-resistant BCR-ABLT315I B-ALL cells
Supplemental data from Bone Marrow Cell Trafficking Analyzed by 89Zr-oxine Positron Emission Tomography in a Murine Transplantation Model
Authors: Asiedu Kingsley O. , Koyasu Sho , Szajek Lawrence P. , Choyke Peter L. , Sato Noriko
Published: April 2023

Supplemental Materials and Methods, Supplemental Figures.
Supplementary Figures from Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer
Authors: Torres-Adorno Angie M. , Lee Jangsoon , Kogawa Takahiro , Ordentlich Peter , Tripathy Debu , Lim Bora , Ueno Naoto T.
Published: April 2023

Supplementary Figure S1. Entinostat induces increased phosphorylation/activation of the pro-survival ERK pathway in IBC cell lines. Supplementary Figure S2. Increased NOXA gene promoter acetylation levels following entinostat treatment. Supplementary Figure S3. Basal MCL1 protein expression is present in most TNBC and IBC cell lines. Supplementary Figure S4. TNBC and IBC cell lines overexpressing NOXA after entinostat treatment exhibit synergy of combination treatment with pimasertib. Supplementary Figure S5. Low-NOXA-inducible HCC1806 cell line did not respond to entinostat and pimasertib single or combination treatment. Supplementary Figure S6. Higher and lower doses of entinostat and pimasertib combination treatment induce tumor regression in IBC and TNBC xenograft models.
Supplementary Table 1 from Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide
Authors: Calagua Carla , Russo Joshua , Sun Yue , Schaefer Rachel , Lis Rosina , Zhang Zhenwei , Mahoney Kathleen , Bubley Glenn J. , Loda Massimo , Taplin Mary-Ellen , Balk Steven P. , Ye Huihui
Published: April 2023

Distribution patterns of PD-L1(+) tumor cells in hormone-naÃ¯ve PCa.
Supplementary Table 3 from Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer
Authors: Flanagan James M. , Wilson Angela , Koo Chail , Masrour Nahal , Gallon John , Loomis Erick , Flower Kirsty , Wilhelm-Benartzi Charlotte , Hergovich Alexander , Cunnea Paula , Gabra Hani , Braicu Elena Ioana , Sehouli Jalid , Darb-Esfahani Silvia , Vanderstichele Adriaan , Vergote Ignace , Kreuzinger Caroline , Castillo-Tong Dan Cacsire , Wisman G. Bea A. , Berns Els MJJ , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S3 - Cox Proportional Hazards Regression models
Supplementary Figure 2 from Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer
Authors: Sabbaghi MohammadA , Gil-Gómez Gabriel , Guardia Cristina , Servitja Sonia , Arpí Oriol , García-Alonso Sara , Menendez Silvia , Arumi-Uria Montserrat , Serrano Laia , Salido Marta , Muntasell Aura , Martínez-García Maria , Zazo Sandra , Chamizo Cristina , González-Alonso Paula , Madoz-Gúrpide Juan , Eroles Pilar , Arribas Joaquin , Tusquets Ignasi , Lluch Ana , Pandiella Atanasio , Rojo Federico , Rovira Ana , Albanell Joan
Published: April 2023

Representative immunohistochemistry images of control and 765 T-DM1 treated explant obtained from a liver metastasis.
Supplementary Figure 3 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Flavopiridol treatment decreases proliferation and increases apoptosis in MYC-driven medulloblastoma cell lines
Supplementary Figure 2 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Hits of the DiSCoVER analysis
Supplementary Figure 1 from DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets
Authors: Hanaford Allison R. , Archer Tenley C. , Price Antoinette , Kahlert Ulf D. , Maciaczyk Jarek , Nikkhah Guido , Kim Jong Wook , Ehrenberger Tobias , Clemons Paul A. , Dančík Vlado , Seashore-Ludlow Brinton , Viswanathan Vasanthi , Stewart Michelle L. , Rees Matthew G. , Shamji Alykhan , Schreiber Stuart , Fraenkel Ernest , Pomeroy Scott L. , Mesirov Jill P. , Tamayo Pablo , Eberhart Charles G. , Raabe Eric H.
Published: April 2023

Detailed diagram of the workflow of the DiSCoVER work flow
Supplemental Table 2 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Table 2: Pathologic complete response rates by route of vaccine administration and ER status in 42 DCIS patients
Supplemental Figure 2 from Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2pos DCIS Independent of Route: Results of Randomized Selection Design Trial
Authors: Lowenfeld Lea , Mick Rosemarie , Datta Jashodeep , Xu Shuwen , Fitzpatrick Elizabeth , Fisher Carla S. , Fox Kevin R. , DeMichele Angela , Zhang Paul J. , Weinstein Susan P. , Roses Robert E. , Czerniecki Brian J.
Published: April 2023

Supplemental Figure 2: Individual CD4pos Th1 immune responses in the peripheral blood by vaccination route (Panel A: intralesional (IL), Panel B: intranodal (IN), Panel C: intralesional and intranodal (ILN)).
Supplementary Table S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Authors: Tran Hung C. , Wan Zesheng , Sheard Michael A. , Sun Jianping , Jackson Jeremy R. , Malvar Jemily , Xu Yibing , Wang Larry , Sposto Richard , Kim Eugene S. , Asgharzadeh Shahab , Seeger Robert C.
Published: April 2023

Supplementary Table S1 is a list of antibodies used in the study. It has been updated to include antibodies used in experiments requested by reviewer #3.
Table S3 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

Blood biochemistry of mice treated with liposomal miR-34a or control mimic.
Supplementary Figure S2 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Authors: Tran Hung C. , Wan Zesheng , Sheard Michael A. , Sun Jianping , Jackson Jeremy R. , Malvar Jemily , Xu Yibing , Wang Larry , Sposto Richard , Kim Eugene S. , Asgharzadeh Shahab , Seeger Robert C.
Published: April 2023

Supplementary Figure S2 shows the results of intracellular staining of aNK cells for perforin and granzyme A, as requested by reviewer #3.
Figure S5 from Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion
Authors: Bayraktar Recep , Ivan Cristina , Bayraktar Emine , Kanlikilicer Pinar , Kabil Nashwa N. , Kahraman Nermin , Mokhlis Hamada A. , Karakas Didem , Rodriguez-Aguayo Cristian , Arslan Ahmet , Sheng Jianting , Wong Stephen , Lopez-Berestein Gabriel , Calin George A. , Ozpolat Bulent
Published: April 2023

Schematic model of the regulatory pathway involving miR-34a in triple-negative breast cancer.
Supplemental material 3: Impact of the significance level from Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design
Authors: Matsui Shigeyuki , Crowley John
Published: April 2023

Impact of the significance level
Supplementary Legends from The NOTCH4–HEY1 Pathway Induces Epithelial–Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma
Authors: Fukusumi Takahito , Guo Theresa W. , Sakai Akihiro , Ando Mizuo , Ren Shuling , Haft Sunny , Liu Chao , Amornphimoltham Panomwat , Gutkind J. Silvio , Califano Joseph A.
Published: April 2023

Supplementary Legends
Treg viability, Ki-67 expression and Foxp3 expression were tested after being treated with IFN-γ for 48 hours from Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients
Authors: Liu Zhuqing , McMichael Elizabeth L. , Shayan Gulidanna , Li Jing , Chen Kevin , Srivastava Raghvendra , Kane Lawrence P. , Lu Binfeng , Ferris Robert L.
Published: April 2023

After sorting Tim-3+ CD4+CD25hiCD127- and Tim-3- CD4+CD25hiCD127- cells from HNSCC TIL, they were treated with IL-2 (200 IU/ml) with or without IFN- γ (200ng/ml) for 48 hours. Viability factor (A), Foxp3 (A) and ki-67 expression (B) were tested by flow cytometry.
Supplementary Figures from AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non–Small Cell Lung Cancer Cells Following EGFR Inhibition
Authors: Scarborough Hannah A. , Helfrich Barbara A. , Casás-Selves Matias , Schuller Alwin G. , Grosskurth Shaun E. , Kim Jihye , Tan Aik-Choon , Chan Daniel C. , Zhang Zhiyong , Zaberezhnyy Vadym , Bunn Paul A. , DeGregori James
Published: April 2023

Supplementary Figures
Supplementary Tables S1-S5 from A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses
Authors: Matei Daniela , Ghamande Sharad , Roman Lynda , Alvarez Secord Angeles , Nemunaitis John , Markham Merry Jennifer , Nephew Kenneth P. , Jueliger Simone , Oganesian Aram , Naim Sue , Su Xiang Yao , Keer Harold , Azab Mohammad , Fleming Gini F.
Published: April 2023

Table S1. Efficacy Table S2. Descriptive Statistics of Guadecitabine Plasma Pharmacokinetic Parameters Table S3. Descriptive Statistics of Decitabine Plasma Pharmacokinetic Parameters Table S4. Genes Tested for Methylation and Expression Analysis of Tumor Biopsies Table S5. All AEs of CTCAE Grade 3 or Higher
table 1 a from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental table 1A List of miRNAs, miRBase accession number and mature sequence of 46 selected-miRNAs used to build the Firefly 46plex circulating custom panel. There miRNAs have previously been linked to pancreatic cancer or to KRAS.
sup 3 from Personalized RNA Medicine for Pancreatic Cancer
Authors: Gilles Maud-Emmanuelle , Hao Liangliang , Huang Ling , Rupaimoole Rajesha , Lopez-Casas Pedro P. , Pulver Emilia , Jeong Jong Cheol , Muthuswamy Senthil K. , Hidalgo Manuel , Bhatia Sangeeta N. , Slack Frank J.
Published: April 2023

Supplemental Figure 3. A) iRGD-TAMRA (red) binding after 15 min at 4 degree in normal cells (Low integrins-NRP1) and in human and mice PDAC cells (High integrins-NRP1). Scale bars 200μm B) qRT-PCR of miR-21-5p expression after treatment of PANC1, BxPC3 and PL-45 cells with TPN-21 at the dose of 100nM after 48h. C) Representation of 3D-model treatment course with TPN-21. For qPCR each miRNA sample was normalized on the basis of its 18s content. Error bars, mean {plus minus} s.d *P = 0.01-0.05; **P = 0.001-0.01; ***P < 0.001; ****P < 0.0001 N.S., not significant, two-tailed t-test; n = 3 biological replicates.
Sup. Figure 7: Knockdown of NTRK1 but not of VEGFR-2 or MET inhibited the viability of KM12SM-ER cells in vitro. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

KM12SM-ER cells were treated with siRNAs specific for NTRK1 (siNTRK), VEGFR-2 (siVEGFR-2), MET (siMET), or a scrambled control (siSCR). (A, C) The expression of TRK-A, VEGFR-2 and MET was determined by western blot. (B, D) Cell viability was determined using a CCK-8 kit. Data (mean {plus minus} SD) shown are representative of three independent experiments with similar results. *P < 0.05 as determined with the Student's t-test, compared with siSCR.
Sup. Figure 5: Entrectinib suppressed phosphorylation of TRK-A with G667C mutation slightly and inhibited phosphorylation of ERK transiently. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

Tumor cells were treated with 10nM of drugs for indicated time, and harvested lysates were assessed by western blotting.
Sup. Figure 4: Foretinib and nintedanib inhibited p TRK-A in KM12SM-ER cells more efficiently than that in KM12SM cells. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

Tumor cells were treated with various concentrations of drugs for 4 h, and harvested lysates were assessed by western blotting.
Sup. Figure 3: Foretinib and nintedanib inhibited the TRK-A in the kinase inhibition profile assay. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

The IC50 value of entrectinib, foretinib and nintedanib against TRK-A, TRK-B and TRK-C human kinases was determined by SignalChem's target profiling service (SignalChem, Richmond, BC, Canada). SignalChem uses a radioisotope assay format for profiling evaluation of all kinase and assays (in duplicate) were performed at 22oC for 30 min in a final volume of 25 mL. The assay was initiated by the addition of 33P-ATP and the reaction mixture incubated at room temperature 22oC for 30 minutes. After the incubation period, the assay was terminated by spotting 10 mL of the reaction mixture onto Multiscreen phosphocellulose P81 plate. The Multiscreen phosphocellulose P81 plate was washed 3 times for approximately 15 minutes each in a 1% phosphoric acid solution. The radioactivity on the P81 plate was counted in the presence of scintillation fluid in a Trilux scintillation counter. For detailed assay conditions for each protein kinase target, please see website (www.signalchem.com).
Sup. Figure 1: EGFP-Eluc gene transfection did not affect the sensitivity of KM12SM cells to entrectinib. from Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model
Authors: Nishiyama Akihiro , Yamada Tadaaki , Kita Kenji , Wang Rong , Arai Sachiko , Fukuda Koji , Tanimoto Azusa , Takeuchi Shinji , Tange Shoichiro , Tajima Atsushi , Furuya Noritaka , Kinoshita Takayoshi , Yano Seiji
Published: April 2023

KM12SM and EGFP-Eluc-transfected KM12SM (KM12SM/Eluc) cells (2 Ã- 103 per well) were incubated with various concentrations of entrectinib in 96-well flat plates for 72 h. Cell viability was determined using a CCK-8 kit. Data (mean {plus minus} SD of triplicate cultures) shown are representative of three independent experiments with similar results.
Movie S6 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
Authors: Zhang Gao , Wu Lawrence W. , Mender Ilgen , Barzily-Rokni Michal , Hammond Marc R. , Ope Omotayo , Cheng Chaoran , Vasilopoulos Themistoklis , Randell Sergio , Sadek Norah , Beroard Aurelie , Xiao Min , Tian Tian , Tan Jiufeng , Saeed Umar , Sugarman Eric , Krepler Clemens , Brafford Patricia , Sproesser Katrin , Murugan Sengottuvelan , Somasundaram Rajasekharan , Garman Bradley , Wubbenhorst Bradley , Woo Jonathan , Yin Xiangfan , Liu Qin , Frederick Dennie T. , Miao Benchun , Xu Wei , Karakousis Giorgos C. , Xu Xiaowei , Schuchter Lynn M. , Mitchell Tara C. , Kwong Lawrence N. , Amaravadi Ravi K. , Lu Yiling , Boland Genevieve M. , Wei Zhi , Nathanson Katherine , Herbig Utz , Mills Gordon B. , Flaherty Keith T. , Herlyn Meenhard , Shay Jerry W.
Published: April 2023

Time-lapse imaging of A375(Fucci2)-CR cells treated with 6-thio-dG.
Supplemental Figure 4 from Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
Authors: Loree Jonathan M. , Pereira Allan A.L. , Lam Michael , Willauer Alexandra N. , Raghav Kanwal , Dasari Arvind , Morris Van. K , Advani Shailesh , Menter David G. , Eng Cathy , Shaw Kenna , Broaddus Russell , Routbort Mark J. , Liu Yusha , Morris Jeffrey S. , Luthra Rajyalakshmi , Meric-Bernstam Funda , Overman Michael J. , Maru Dipen , Kopetz Scott
Published: April 2023

Summary of the relative prognostic and mutational impact of tumor location in metastatic colorectal cancer. Sub-caption: Relative prevalence of mutations at each site was compared to the median prevalence across all sites and used to calculate relative font size for each gene name. Hazard ratios displayed in the figure utilize rectal location as the reference category.
Figure S3 from Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy
Authors: Wang Qiongyao , Zeng Fanrui , Sun Yanqin , Qiu Qianqian , Zhang Jian , Huang Weimei , Huang Jie , Huang Xiaomin , Guo Linlang
Published: April 2023

Figure S3. Knockdown of PFKFB4 affects autophagy in SCLC cells.
Figure S1 from Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy
Authors: Wang Qiongyao , Zeng Fanrui , Sun Yanqin , Qiu Qianqian , Zhang Jian , Huang Weimei , Huang Jie , Huang Xiaomin , Guo Linlang
Published: April 2023

Figure S1. Modulated expression of Etk in SCLC cells.
Supplementary Table 4 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study
Authors: Nieuweboer Annemieke J.M. , de Graan Anne-Joy M. , Hamberg Paul , Bins Sander , van Soest Robert J. , van Alphen Robbert J. , Bergman Andries M. , Beeker Aart , van Halteren Henk , ten Tije Albert J. , Zuetenhorst Hanneke , van der Meer Nelly , Chitu Dana , de Wit Ronald , Mathijssen Ron H.J.
Published: April 2023

Patient diaries' information
Supplementary Text, Figures and Tables from Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Authors: Sveen Anita , Bruun Jarle , Eide Peter W. , Eilertsen Ina A. , Ramirez Lorena , Murumägi Astrid , Arjama Mariliina , Danielsen Stine A. , Kryeziu Kushtrim , Elez Elena , Tabernero Josep , Guinney Justin , Palmer Hector G. , Nesbakken Arild , Kallioniemi Olli , Dienstmann Rodrigo , Lothe Ragnhild A.
Published: April 2023

This file contains Supplementary Text, Supplementary Figures S1-S13 and Supplementary Tables S1, S3-S5, S9-S10, S14-S15, S18-S19. Supplementary Fig. S1. Validation of prognostic associations and biological properties of the CMS groups in primary CRCs Supplementary Fig. S2. The original CMS classifier fails to accurately identify the CMS groups in CRC cell lines Supplementary Fig. S3. Principal components analysis of cell lines based on gene expression Supplementary Fig. S4. Assessment of misclassification risk of CRC cell lines Supplementary Fig. S5. Additional template gene filter for classifier genes expressed in the tumor stroma Supplementary Fig. S6. Biological characteristics of the CMS groups are recapitulated in PDX models of CRC Supplementary Fig. S7. CRC cell lines analyzed by drug screening are representative with respect to gene expression and CMS groups Supplementary Fig. S8. Principal components analysis of in vitro drug screen data Supplementary Fig. S9. Validation of strong relative activity of EGFR inhibition in CMS2 Supplementary Fig. S10. Drug response analyses between CMS1/4 and CMS2/3 cell lines Supplementary Fig. S11. In vitro validation of strong relative sensitivity to HSP90 inhibition in CMS1 and CMS4 cell lines in published data Supplementary Fig. S12. Up-regulation of heat shock response in cell lines treated with luminespib Supplementary Fig. S13. Poor response to fluoropyrimidines in CMS4 cell lines Supplementary Table S1. Clinicopathological and molecular characteristics of consecutive patient series (n = 409) Supplementary Table S3. Enrichment of molecular characteristics among CMS groups in primary CRC Supplementary Table S4. Enrichment of clinicopathological characteristics among CMS groups in primary CRC Supplementary Table S5. Multivariable survival analyses Supplementary Table S9. Classification concordance between the original and new cancer cell-adapted CMS classifier in CRC cell lines Supplementary Table S10. Enrichment of molecular characteristics among CMS groups of CRC cell lines Supplementary Table S14. Overview of the molecular target classes for the highthroughput drug screening library Supplementary Table S15. Drugs with strong effect in MSI+ versus MSS cell lines Supplementary Table S18. Drugs with strong relative activity in CMS2 Supplementary Table S19. Differential gene expression in response to luminespib treatment
Supplementary Figure Legends from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Legends for all included Supplementary Figures
Supplementary Tables from Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Authors: Sveen Anita , Bruun Jarle , Eide Peter W. , Eilertsen Ina A. , Ramirez Lorena , Murumägi Astrid , Arjama Mariliina , Danielsen Stine A. , Kryeziu Kushtrim , Elez Elena , Tabernero Josep , Guinney Justin , Palmer Hector G. , Nesbakken Arild , Kallioniemi Olli , Dienstmann Rodrigo , Lothe Ragnhild A.
Published: April 2023

This file contains Supplementary Tables S2, S6-S8, S11-S13, and S16-S17. Supplementary Table S2. Overview and CMS groups of CRC cell line Supplementary Table S6. Gene set analysis among CMS groups in primary CRCs Supplementary Table S7. Potential template genes and filtering steps Supplementary Table S8. Template genes for the adapted CMS classifier Supplementary Table S11. Gene set analyses among CMS groups in CRC cell lines Supplementary Table S12. Assessment of misclassification risk in CRC cell lines Supplementary Table S13. CMS classification of PDX models by adapted CMS classifier Supplementary Table S16. Differential drug sensitivity between cell lines of individual CMS groups Supplementary Table S17. Drug response data for 27 selected drugs in 29 individual cell lines
Supplementary Figure 5 from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Heat map of cell cycle gene expression. Gene expression was normalized and compared between the primary MTC, metastasis one, and metastasis two lesions from the whole transcriptome RNA-seq data. Purple indicates lower and yellow indicates higher expression. Values to generate colors are z-scores across each genes' relative transcript levels [log2(FPKM)].
Supplementary Figure 3 from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Doubling time of calcitonin and CEA for patient #12 was suggestive of progressive disease. Patient #12 experienced best response 434 days after starting vandetanib, with stable lesions in the thyroid bed (showed on T2-weighted MRI of the neck, A) and the mediastinum (showed on CT of the chest, B). In August 2016, the sum of longest diameter (per RECIST) of target lesions was consistent with SD (C,D) (note that not all target lesions are shown). Biomarker response in the two years prior (E) showed CEA doubling time 1.2 years (F) and calcitonin doubling time 1.67 years (G). Patient #12 was confirmed to have PD via RECIST February 2017.
Legends of Figs S1 to S8 unmarked from Development of a Function-Blocking Antibody Against Fibulin-3 as a Targeted Reagent for Glioblastoma
Authors: Nandhu Mohan S. , Behera Prajna , Bhaskaran Vivek , Longo Sharon L. , Barrera-Arenas Lina M. , Sengupta Sadhak , Rodriguez-Gil Diego J. , Chiocca E. Antonio , Viapiano Mariano S.
Published: April 2023

Legends of Figs S1 to S8, unmarked version
Supplementary Figure 2 from Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib
Authors: Kraft Ira L. , Akshintala Srivandana , Zhu Yuelin , Lei Haiyan , Derse-Anthony Claudia , Dombi Eva , Steinberg Seth M. , Lodish Maya , Waguespack Steven G. , Kapustina Oxana , Fox Elizabeth , Balis Frank M. , Merino Maria J. , Meltzer Paul S. , Glod John W. , Shern Jack F. , Widemann Brigitte C.
Published: April 2023

Doubling time of calcitonin and CEA during vandetanib therapy. Calcitonin and CEA slopes and doubling times were calculated from the change during the initial four months of vandetanib (A,B), from values the year before experiencing PD or the data cutoff (C,D) and in patients that experienced progressive disease (E).
Supplementary Tables from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Table 1: Patients Characteristics Supplementary Table 2: Comparative transduction of melanoma cell cultures
Supplementary Figure S2 from Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells
Authors: Gammaitoni Loretta , Giraudo Lidia , Macagno Marco , Leuci Valeria , Mesiano Giulia , Rotolo Ramona , Sassi Francesco , Sanlorenzo Martina , Zaccagna Alessandro , Pisacane Alberto , Senetta Rebecca , Cangemi Michela , Cattaneo Giulia , Martin Valentina , Coha Valentina , Gallo Susanna , Pignochino Ymera , Sapino Anna , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

Supplementary Figure S2: Immunophenotype of patient-derived CIK cells and CIK cell in vitro activity
Supplemental Table S6 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S6. Muliple metrics were used to calculate synergy of all compounds tested from MIPE 4.0 library in combination with PF-562271. Highlighted in green are Pan-Aurora Inhibitors, red are Aurora B inhibitors, and blue are Aurora A inhibitors.
Supplemental Table S4 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S4. Target sequences for sgRNA guides targeting AURKB, AURKA, and FAK genes
Supplemental Table S2 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S2. Target sequences for shRNAs targeting AURKB expression in the Achilles Project
Supplemental Table S1 from High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
Authors: Wang Sarah , Hwang Elizabeth E. , Guha Rajarshi , O'Neill Allison F. , Melong Nicole , Veinotte Chansey J. , Conway Saur Amy , Wuerthele Kellsey , Shen Min , McKnight Crystal , Alexe Gabriela , Lemieux Madeleine E. , Wang Amy , Hughes Emma , Xu Xin , Boxer Matthew B. , Hall Matthew D. , Kung Andrew , Berman Jason N. , Davis Mindy I. , Stegmaier Kimberly , Crompton Brian D.
Published: April 2023

Supplemental Table S1. List of compounds in MIPE 4.0 compound library
Supplementary Table S2 from Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Krumbholz Manuela , Hellberg Julia , Steif Benedikt , Bäuerle Tobias , Gillmann Clarissa , Fritscher Torsten , Agaimy Abbas , Frey Benjamin , Juengert Joerg , Wardelmann Eva , Hartmann Wolfgang , Juergens Heribert , Dirksen Uta , Metzler Markus
Published: April 2023

Sequences of primers and probes used for quantification of genomic fusion sequences
Supplementary Figure 1 from A Prognostic Bio-Model Based on SQSTM1 and N-Stage Identifies Nasopharyngeal Carcinoma Patients at High Risk of Metastasis for Additional Induction Chemotherapy
Authors: Yang Qi , Zhang Meng-Xia , Zou Xiong , Liu You-Ping , You Rui , Yu Tao , Jiang Rou , Zhang Yi-Nuan , Cao Jing-Yu , Hong Ming-Huang , Liu Qing , Guo Ling , Kang Tie-Bang , Zhu Xiao-Feng , Chen Ming-Yuan
Published: April 2023

SQSTM1 is associated with EMT-related proteins expression in vivo.
Supplementary Figure S1 from Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma
Authors: Krumbholz Manuela , Hellberg Julia , Steif Benedikt , Bäuerle Tobias , Gillmann Clarissa , Fritscher Torsten , Agaimy Abbas , Frey Benjamin , Juengert Joerg , Wardelmann Eva , Hartmann Wolfgang , Juergens Heribert , Dirksen Uta , Metzler Markus
Published: April 2023

Tumor engraftment in NMRI nu/nu and NSG mice after s.c. (A) and i.v. (B) injection of EWSR1-FLI1 positive cell lines EwS type 1 (A673 and TC-71) or type 2 (VH-64 and RD-ES). (C) Localization of metastases after i.v. injection of EwS cells in NMRI nu/nu and NSG mice. T2-weighted images from ultra high field MRI show the presence of organ metastases in NSG mice ex vivo (Lu, Lung; H, Heart; B, Bone; M, Muscle; Li, Liver; K, Kidney; O, Ovary; *, Tumor). H&E stain and CD99+ immunostaining show tumor infiltration with high proliferation rate (60%).
Supplementary Table 1 from HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Authors: Wang Dongsheng , Qian Guoqing , Zhang Hongzheng , Magliocca Kelly R. , Nannapaneni Sreenivas , Amin A.R.M. Ruhul , Rossi Michael , Patel Mihir , El-Deiry Mark , Wadsworth J. Trad , Chen Zhengjia , Khuri Fadlo R. , Shin Dong M. , Saba Nabil F. , Chen Zhuo G.
Published: April 2023

Patients Disease Characteristics
Figure S4 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 4. (A) Dot plot representations of OCI-AML3-expressing roGFP2 cells to evaluate glutathione or hydrogen peroxide (H2O2) redox potential in cytoplasmic or mitochondrial compartments. Each of the four roGFP2 stable cell lines were transduced with lentiviruses expressing CTRL shRNA or PKCÎµ shRNA_1 or _2 and analyzed by flow cytometry 5 days after transduction. (B) Represents the individual experiments of the combined data presented in figure 2A. (**p{less than or equal to}0.01; ***p{less than or equal to}0.001; ****p<0.0001)
Figure S3 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental Figure 3. (A) Schematic representation of the experimental design for analysis of patient derived (PD) - AML samples. (B) Ex vivo growth curve analysis of patient-derived AML sample TUHS-AML-013 transduced with lentiviruses co-expressing GFP and CTRL or PKCÎµ shRNA_1 and then analyzed by flow cytometry for the GFP+, CD45+, PI- cells every 3 days following transduction as discussed in the legend of Figure 2 (*p{less than or equal to}0.05). (C) NOMO1 and (D) THP-1 cells were transduced with CTRL shRNA or PKCÎµ shRNAs and stained 5 days later with CellROX. The left panel is an illustrative histogram plot of a single experiment and the right panel shows the Median Fluorescence Intensity (MFI) of CellROX (**p{less than or equal to}0.01; ****p<0.0001). Data are represented as the mean {plus minus} SD of three technical replicates.
Figure S2 from Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia
Authors: Di Marcantonio Daniela , Martinez Esteban , Sidoli Simone , Vadaketh Jessica , Nieborowska-Skorska Margaret , Gupta Anushk , Meadows Jake M. , Ferraro Francesca , Masselli Elena , Challen Grant A. , Milsom Michael D. , Scholl Claudia , Fröhling Stefan , Balachandran Siddharth , Skorski Tomasz , Garcia Benjamin A. , Mirandola Prisco , Gobbi Giuliana , Garzon Ramiro , Vitale Marco , Sykes Stephen M.
Published: April 2023

Supplemental figure 2. (A) Schematic representation of the in vivo experimental conditions carried out in Figures 1A-C. (B) FACS gating strategy for sorting 7AAD-/GFP+ mouse MLL-AF9 leukemia cells transduced with CTRL shRNA or PkcÎµ shRNA. Cell sorted 48 hours post-transduction and FACS isolated cells were analyzed for purity. (C) Western blot analysis of PKCÎµ expression in mouse MLL-AF9 leukemia cells transduced with CTRL shRNA or PkcÎµ shRNA GFP and sorted 24, 48 and 72 hours after transduction. The original exposure is shown in the upper panel. Brightness was modified in the lowest panel to clarify differences between conditions. (D & E) In vitro competitive growth curve of mouse MLL-AF9 leukemia cells transduced with CTRL shRNA or PkcÎµ shRNA were analyzed at the indicated time points for (D) percentage of GFP-positive (% GFP+) cells plotted versus (E) fold change in the percentage of GFP-positive cells relative to Day 2 post-transduction. The data is representative on one experiment.
Supplementary Figure 2 from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

Detection of AR-V7, AR-FL and PSA transcripts in DU145 spiked with 22RV1 cells
Supplementary Figure 1 from Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer
Authors: Qu Fangfang , Xie Wanling , Nakabayashi Mari , Zhang Haitao , Jeong Seong Ho , Wang Xiaodong , Komura Kazumasa , Sweeney Christopher J. , Sartor Oliver , Lee Gwo-Shu Mary , Kantoff Philip W.
Published: April 2023

Analytical sensitivity and specificity of ddPCR determination
Supplement Figure 3 from Extracellular Vesicles Released by Cardiomyocytes in a Doxorubicin-Induced Cardiac Injury Mouse Model Contain Protein Biomarkers of Early Cardiac Injury
Authors: Yarana Chontida , Carroll Dustin , Chen Jing , Chaiswing Luksana , Zhao Yanming , Noel Teresa , Alstott Michael , Bae Younsoo , Dressler Emily V. , Moscow Jeffrey A. , Butterfield D. Allan , Zhu Haining , St. Clair Daret K.
Published: April 2023

Western blots indicating PYGB, PYGM, and PYGL are tissue-specific protein. PYGB is highly expressed in heart and brain. PYGM is highly expressed in skeletal muscle. PYGL is highly expressed in liver. Vinculin and tubulin were used as appropriate positive controls.
Supplementary fig 4 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
Authors: Piulats Josep M. , Vidal August , García-Rodríguez Francisco J. , Muñoz Clara , Nadal Marga , Moutinho Catia , Martínez-Iniesta María , Mora Josefina , Figueras Agnés , Guinó Elisabet , Padullés Laura , Aytés Àlvaro , Molleví David G. , Puertas Sara , Martínez-Fernández Carmen , Castillo Wilmar , Juliachs Merce , Moreno Victor , Muñoz Purificación , Stefanovic Milica , Pujana Miguel A. , Condom Enric , Esteller Manel , Germà Josep R. , Capella Gabriel , Farré Lourdes , Morales Albert , Viñals Francesc , García-del-Muro Xavier , Cerón Julián , Villanueva Alberto
Published: April 2023

Physical and Functional interactions of proteins encoded by 9q32-q33.1 genes expressed in PDOXs of this study
Supplementary fig 2 from Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing Agent
Authors: Piulats Josep M. , Vidal August , García-Rodríguez Francisco J. , Muñoz Clara , Nadal Marga , Moutinho Catia , Martínez-Iniesta María , Mora Josefina , Figueras Agnés , Guinó Elisabet , Padullés Laura , Aytés Àlvaro , Molleví David G. , Puertas Sara , Martínez-Fernández Carmen , Castillo Wilmar , Juliachs Merce , Moreno Victor , Muñoz Purificación , Stefanovic Milica , Pujana Miguel A. , Condom Enric , Esteller Manel , Germà Josep R. , Capella Gabriel , Farré Lourdes , Morales Albert , Viñals Francesc , García-del-Muro Xavier , Cerón Julián , Villanueva Alberto
Published: April 2023

Comparative histological analysis of original non-treated orthoxenografts and their pairs with acquired resistance to CDDP after five cycles of treatment in mice
Table S4 from Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma
Authors: Sternberg Cora N. , Donskov Frede , Haas Naomi B. , Doehn Christian , Russo Paul , Elmeliegy Mohamed , Baneyx Guillaume , Banerjee Hiya , Aimone Paola , Motzer Robert J.
Published: April 2023

al population PK parameters for pazopanib
Supplementary Data: Table S1, Figure S1 from Exploration of a Novel Intermediate Response Endpoint in Immunotherapy Clinical Studies
Authors: Gao Xin , Zhang Lijun , Sridhara Rajeshwari
Published: April 2023

Key baseline demographic and characteristics; Hazard ratio from Cox model
Supplementary Figures and Table from Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers
Authors: Hammerlindl Heinz , Ravindran Menon Dinoop , Hammerlindl Sabrina , Emran Abdullah Al , Torrano Joachim , Sproesser Katrin , Thakkar Divya , Xiao Min , Atkinson Victoria G. , Gabrielli Brian , Haass Nikolas K. , Herlyn Meenhard , Krepler Clemens , Schaider Helmut
Published: April 2023

Supplementary Figure 1, Sorafenib in combination with aspirin but not COX1/2 inhibitors synergistically induces cell death in RAS or RAF mutant cancer cell lines. Supplementary Figure 2, the combination of sorafenib/aspirin activates ERK and AMPK signalling after 4 hours of drug exposure. Supplementary Figure 3, MEK, pan-RAF and AMPK inhibitors diminish sorafenib/aspirin induced cell death. Supplementary Figure 4, high concentrations of dabrafenib in combination with aspirin reduces cell viability in RAS mutant cancer cells. Supplementary Figure 5, immunohistochemistry of phosphor-ERK in A549 xenografts treated with vehicle, sorafenib, aspirin or combined sorafenib/aspirin. Supplementary Table 1, list of used antibodies.
Supplementary methods from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary methods
Figure S9 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 9: STH0047 treatment reduces CD31+ endothelial cells in syngeneic SMA-560-bearing mice.
Table S1 from Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
Authors: Echavarria Isabel , López-Tarruella Sara , Picornell Antoni , García-Saenz Jose Ángel , Jerez Yolanda , Hoadley Katherine , Gómez Henry L. , Moreno Fernando , Monte-Millan María Del , Márquez-Rodas Iván , Alvarez Enrique , Ramos-Medina Rocío , Gayarre Javier , Massarrah Tatiana , Ocaña Inmaculada , Cebollero María , Fuentes Hugo , Barnadas Agusti , Ballesteros Ana Isabel , Bohn Uriel , Perou Charles M. , Martin Miguel
Published: April 2023

Table S1 Response among mutation carriers among mutation carriers (number of patients.)
Figure S8 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 8: ISTH1047 or ISTH0047 treatment reduce the invasiveness of experimental gliomas invivo.
Figure S7 from Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas
Authors: Papachristodoulou Alexandros , Silginer Manuela , Weller Michael , Schneider Hannah , Hasenbach Kathy , Janicot Michel , Roth Patrick
Published: April 2023

Supplementary Figure 7: Systemic treatment of glioma-bearing mice with ISTH1047 or ISTH0047 inhibits tumor growth.
Figure S1, Table S1 from Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone
Authors: Dugan James P. , Haverkos Bradley M. , Villagomez Lynda , Martin Ludmila K. , Lustberg Mark , Patton John , Martin Marisa , Huang Ying , Nuovo Gerard , Yan Fengting , Cavaliere Robert , Fingeroth Joyce , Kenney Shannon C. , Ambinder Richard F. , Lozanski Gerard , Porcu Pierluigi , Caligiuri Michael A. , Baiocchi Robert A.
Published: April 2023

Dosing schedule figure Dose reduction table